The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA Damage

We previously reported that 3 p53 wild type (wt) MYCN amplified (MNA) neuroblastoma cell lines failed to G1 arrest after DNA damage despite induction of p53, p21WAF1 and MDM2. We hypothesised that this was due to high MYCN expression. p53 responses to DNA damage were examined in an additional 13 p53 wt neuroblastoma cell lines. MNA was significantly associated with a failure to G1 arrest after DNA damage (p

[1]  N. Cheung,et al.  The MYCN enigma: significance of MYCN expression in neuroblastoma. , 2006, Cancer research.

[2]  U. Kees,et al.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.

[3]  R. Marchelli,et al.  Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis , 2005, Molecular Cancer Therapeutics.

[4]  A. Pession,et al.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Puisieux,et al.  Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. , 2004, Cancer cell.

[6]  M. Schwab.  MYCN in neuronal tumours. , 2004, Cancer letters.

[7]  R. Versteeg,et al.  Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. , 2004, Gene.

[8]  J. Herman,et al.  Clustering of hypermethylated genes in neuroblastoma , 2003, Genes, chromosomes & cancer.

[9]  W. Weiss,et al.  Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. , 2003, Journal of the National Cancer Institute.

[10]  Ajay N. Jain,et al.  Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. , 2003, Cancer research.

[11]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[12]  R. Kriwacki,et al.  P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest. , 2003, Cancer research.

[13]  C J Gomer,et al.  Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. , 2001, Cancer research.

[14]  J. Lunec,et al.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. , 2001, The American journal of pathology.

[15]  A. Gartel,et al.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. McKenzie,et al.  Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  U. Galderisi,et al.  Differentiation and apoptosis of neuroblastoma cells: Role of N‐myc gene product , 1999, Journal of cellular biochemistry.

[18]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[19]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[20]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[21]  M. Kastan,et al.  The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. , 1996, The American journal of pathology.

[22]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[23]  U. Kees,et al.  Three neuroblastoma cell lines established from consecutive samples of one patient which show distinct morphologic features, MYCN amplification, and surface marker expression. , 1992, Cancer genetics and cytogenetics.

[24]  S. Cohn,et al.  Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. , 1991, Cancer research.

[25]  H. Hameister,et al.  Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS , 1991, Human Genetics.

[26]  J. Cowell,et al.  Chromosome analysis of human neuroblastoma cell line TR14 showing double minutes and an aberration involving chromosome 1. , 1983, Cancer genetics and cytogenetics.

[27]  F. Gilbert,et al.  Clonal evolution in a human neuroblastoma. , 1983, Journal of the National Cancer Institute.

[28]  L S Freedman,et al.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. , 1978, Cancer research.

[29]  G. S. Sekhon,et al.  Chromosomal aberrations in human neuroblastomas , 1977, Cancer.

[30]  J. Massagué,et al.  Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.

[31]  J. Maris,et al.  Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. , 2001, Cancer research.

[32]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[33]  J. Houghton,et al.  Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. , 1998, Oncology research.

[34]  M. Schwab,et al.  The mycN/max protein complex in neuroblastoma. Short review. , 1995, European journal of cancer.

[35]  N. Ikegaki,et al.  The expression and modulation of proteins associated with physiological cell death in neuroblastoma cells. , 1994, Progress in clinical and biological research.

[36]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[37]  R. Kennett,et al.  High levels of N-myc protein in a neuroblastoma cell line lacking N-myc amplification. , 1991, Progress in clinical and biological research.

[38]  G. Tonini,et al.  A New Human Highly Tumorigenic Neuroblastoma Cell Line with Undetectable Expression of N-myc , 1990, Pediatric Research.

[39]  M. Tomayko,et al.  Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. , 1988, Progress in clinical and biological research.